Effects of anacetrapib in patients with atherosclerotic vascular disease

Effects of anacetrapib in patients with atherosclerotic vascular disease

<p>BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL chole...

Full description

Bibliographic Details
Main Authors:	Bowman, L, Hopewell, J, Chen, F, Wallendszus, K, Stevens, W, Collins, R, Wiviott, S, Cannon, C, Braunwald, E, Sammons, E, Landray, M
Format:	Journal article
Published:	Massachusetts Medical Society 2017

Similar Items

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
by: Sammons, E, et al.
Published: (2021)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
by: Landray, M, et al.
Published: (2017)

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
by: Mathieu R. Brodeur, et al.
Published: (2023-01-01)

Metabolic Syndrome in Patients with Atherosclerotic Vascular Disease
by: Sadaf Zaman
Published: (2016-06-01)

Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
by: Li, J, et al.
Published: (2012)

ASCEND-eye: rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
by: Sammons, E, et al.
Published: (2023)

Atherosclerotic vascular disorders in HIV infected patients
by: John Palios, et al.
Published: (2011-07-01)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
by: Harper, C, et al.
Published: (2021)

The possibility of early detection of atherosclerotic vascular lesions in rheumatic diseases
by: A. N. Bazhenov, et al.
Published: (2013-06-01)

Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the United Kingdom and United States
by: Lui, JNM, et al.
Published: (2023)

Blood microflora of patients with atherosclerotic vascular lesions and microflora of atherosclerotic plaques of carotid arteries
by: Diliara M. Sharifullina, et al.
Published: (2022-01-01)

Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases
by: Matej Samoš, et al.
Published: (2021-01-01)

Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease
by: Dean G. Karalis, et al.
Published: (2023-06-01)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
by: Bulbulia, R, et al.
Published: (2007)

Prevalence of combined atherosclerotic vascular lesions in patients with diabetes mellitus
by: Svetlana Alexandrovna Gracheva, et al.
Published: (2012-03-01)

Underuse of statins in patients with atherosclerotic ischemic stroke in China.
by: Li, X, et al.
Published: (2012)

Novel Biomarkers of Atherosclerotic Vascular Disease—Latest Insights in the Research Field
by: Cristina Andreea Adam, et al.
Published: (2022-04-01)

Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
by: Landray, M, et al.
Published: (2014)

Nitrate intake and atherosclerotic vascular disease mortality: A prospective cohort study
by: L.C. Blekkenhorst, et al.
Published: (2017-06-01)

Effects of extended-release niacin with laropiprant in high-risk patients.
by: Landray, M, et al.
Published: (2014)

Serum Lipoprotein(a) Levels in Patients with Atherosclerotic Peripheral Vascular Disease in Hospital Kuala Lumpur
by: N.A. Hakim, et al.
Published: (2008-01-01)

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
by: Emily Sammons, et al.
Published: (2023-10-01)

Residual risk in patients with atherosclerotic cardiovascular disease
by: E. V. Khazova, et al.
Published: (2023-02-01)

Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes
by: Michał Ząbczyk, et al.
Published: (2021-07-01)

Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease
by: Julius L. Decano, et al.
Published: (2018-08-01)

The role of non-alcoholic fatty liver disease in the formation of atherosclerotic vascular lesions in patients with abdominal obesity
by: N. L. Denisov, et al.
Published: (2018-08-01)

Risk of coronary and other nonstroke vascular death in relation to the presence and extent of atherosclerotic disease at the carotid bifurcation.
by: Touzé, E, et al.
Published: (2006)

Impact of prior myocardial infarction and vascular disease on the risk of subsequent cardiac events among 68 730 patients commencing dialysis.
by: Landray, M, et al.
Published: (2002)

Perivascular adipose tissue in vascular pathologies—a novel therapeutic target for atherosclerotic disease?
by: Yusuke Adachi, et al.
Published: (2023-05-01)

Multiple Atherectomy and Patch Plasty in Diffuse Atherosclerotic Peripheral Vascular Disease: Our Experience
by: Mohit Sharma, et al.
Published: (2016-01-01)

Risk stratification in symptomatic intracranial atherosclerotic disease with conventional vascular risk factors and cerebral haemodynamics
by: Xinyi Leng, et al.

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
by: Kent, S, et al.
Published: (2016)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
by: Harper, C, et al.
Published: (2021)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
by: Harper, C, et al.
Published: (2023)

The Impact of Atherosclerotic Burden on Vascular Outcomes in Patients with Stroke and Atrial Fibrillation: The ATHENA study
by: Andrea Galeazzo Rigutini MD
Published: (2024-04-01)

Caveolin-1 influences vascular protease activity and is a potential stabilizing factor in human atherosclerotic disease.
by: Juan A Rodriguez-Feo, et al.
Published: (2008-01-01)

Atherosclerotic vascular disease and its correlates in stable black South African kidney transplant recipients
by: Oguntola SO, et al.
Published: (2018-07-01)

Prevalence of Atherosclerotic Disease in Microscopic Colitis Patients
by: Paul Hong, et al.
Published: (2023-01-01)